• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419
Citation: YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419
shu

Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example

More Information
    Graphical Abstract
    • Abstract
  • Protease inhibitors(PIs)are a class of antiviral drugs widely used for the treatment of HIV/AIDS. The status of intellectual property of HIV protease inhibitors lopinavir is briefly reviewed in this paper. Based on the indication of Kaletra® , the follow-up studies and generic development of PIs were discussed. It was concluded that the combination of PIs and anti-bacterial/anti-fungal drugs with CYP450 inhibitory effects would be of great use for AIDS and the infectious complications, in the hope of seeking the secondary innovation of other drugs with expired patents in the fields of drug combination and indication expansion.
    • FullText(HTML)
    • References (11)
  • [1]
    Yang QG,He XC,Bai DL.Current status of HIV protease inhibitors[J].Acta Pharm Sin(药学学报),2005,40(5):389-394.
    [2]
    Guo DL, Liu GN, Li J, et al. Improved synthesis of raltegravir[J].J China Pharm Univ(中国药科大学学报),2009,40(4):297-301.
    [3]
    Molla A,Mo HM,Vasavanonda S,et al.In vitro antiviral interaction of lopinavir with other protease inhibitors[J].Antimicrob Agents Ch,2002,46(7):2249-2253.
    [4]
    Liu J,Dong L.The discussion of generic drugs development for Chinese pharmaceutical enterprises[J].Chin Pharm(中国药业),2011,20(16):6-7.
    [5]
    Guo ZR,Zhao HY.Challenges and strategies of drug innovation[J].Acta Pharm Sin(药学学报),2013,48(7):1031-1040.
    [6]
    Aids Map.Fixed-dose combinations[EB/OL].(2011-03-31)[2014-04-09] .http://www.aidsmap.com/Fixed-dosecombinations/page/1729748/.
    [7]
    Walmsley S.Protease inhibitor-based regimens for HIV therapy:safety and efficacy[J].J Acq Imm Def Syn,2007,45(S1):S5-13.
    [8]
    Du HZ,Yang Q,Song JY,et al.Research toward approved drugs for anti-HIV/acquired immunodeficiency syndrome and its complications[J].Chin Pharm J(中国药学杂志),2009,44(2):81-87.
    [9]
    U.S.Food and Drug Administration.Drug development and drug interactions:table of substrates,inhibitors and inducers[EB/OL].(2006-05-01)[2014-05-20] .http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit.
    [10]
    Sanso G.Double capsule for the administration of active principles in multiple therapies:US,6350486B1[P].2002-02-26[2014-05-25] .
    [11]
    Wu JJ,Stranix BR,Ge M,et al.Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors:US,2012/0053139A1[P].2012-05-01[2014-05-25] .
    • Related Articles

  • Related Articles

    [1]YANG Chengwei, GUO Yali, LI Caolong. Synthesis and antibacterial activity of water-soluble limonin benzoylhydrazone derivatives[J]. Journal of China Pharmaceutical University, 2022, 53(3): 273-277. DOI: 10.11665/j.issn.1000-5048.20220303
    [2]GAO Liuzhou, XIE Yusuo, HUANG Wenlong, HU Guoqiang. Synthesis, antibacterial and antitumor activities of 1-cycloproyl-6-fluoro-7-(hydrazone)-quinolin-4(1H)-one-carboxylic acids[J]. Journal of China Pharmaceutical University, 2014, 45(6): 662-664. DOI: 10.11665/j.issn.1000-5048.20140607
    [3]PANG Daorui, LIU Fan, SHI Ying, LIU Jun, SHEN Weizhi, ZOU Yuxiao, LIAO Sentai, XIAO Gengsheng. Antibacterial activity of 10 phenolic compounds from mulberry[J]. Journal of China Pharmaceutical University, 2014, 45(2): 221-226. DOI: 10.11665/j.issn.1000-5048.20140216
    [4]HU Guo-qiang, HOU Li-li, WANG Guo-qiang, DUAN Nan-nan, WEN Xiao-yi, CAO Tie-yao, HUANG Wen-long. Synthesis and antitumor and antibacterial activities of fluoroquinolone C-3 isosteres I.norfloxacin C-3 carbonylhydrazone derivatives[J]. Journal of China Pharmaceutical University, 2012, 43(4): 298-301.
    [5]CHEN Guo-hua, REN Zhong, YANG Yang, WU Fei-hua. Synthesis and antibacterial activity of novel fourth-generation cephalosporin compounds[J]. Journal of China Pharmaceutical University, 2009, 40(5): 395-399.
    [6]Synthesis and Antibacterial Activity of C-2 Sulfur-Bridged Tetracyclofluoroquinolone Antibacterial Agent W1[J]. Journal of China Pharmaceutical University, 2001, (4): 7-11.
    [7]In vitro and In vivo Antibacterial Activities of Fleroxacin Injection[J]. Journal of China Pharmaceutical University, 1997, (5): 53-57.
    [8]Synthesis and Antibacterial Activity of 6, 8-Difluoro Quinolones[J]. Journal of China Pharmaceutical University, 1993, (5): 264-268.
    [9]Antimicrobial Activity (in Vitro) of the Constituents of Bulbus Fritillariae[J]. Journal of China Pharmaceutical University, 1992, (3): 188-189.
    [10]Fang Jingxian, Song Yirong, Bao Yongming. ANTIBACTERIAL ACTIVITIES OF DOXYCYCLINE AND TMP IN COMBINATION[J]. Journal of China Pharmaceutical University, 1984, (3): 54-60.

  • Cited by

    Periodical cited type(5)

    1. 李文花，王岚. 芙蓉尿感清治疗尿路感染作用机制的网络药理学分析. 医学信息. 2024(14): 1-5 .
    2. 吕鑫科，曾爱国. 木犀草素-聚乙二醇400/PVP k30固体分散体的制备及体内外评价. 西北药学杂志. 2023(06): 100-104 .
    3. 夏志丹，张忠元. 载木犀草素纳米胶束的制备及其大鼠体内药动学研究. 中国现代中药. 2023(10): 2179-2185 .
    4. 施敏，杨莉莉，鲍昌昊，马雯雯，程寒. 木犀草素检测方法研究进展. 化学研究. 2022(01): 85-93 .
    5. 程雨馨，周思琪，张兴彩. 基于GEO差异分析及网络药理学探究银杏叶治疗肺间质纤维化的作用机制. 云南中医中药杂志. 2022(10): 23-30 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (1185) PDF downloads (2931) Cited by(7)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：299148

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return